Compare IDEXX Laboratories, Inc. (IDXX) vs YieldMax MSTR Option Income Strategy ETF (MSTY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IDEXX Laboratories, Inc. vs YieldMax MSTR Option Income Strategy ETF — how do they compare? IDEXX Laboratories, Inc. trades at $572.98 (market cap $46.22B), while YieldMax MSTR Option Income Strategy ETF trades at $12.29. The key difference: IDEXX Laboratories, Inc. is trading nearer its 52-week high, YieldMax MSTR Option Income Strategy ETF nearer its low. Which is the better fit depends on your goals.
| IDXX | MSTY | |
|---|---|---|
Market Cap | $46.22B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $766.68 | $95.95 |
52-Week Low | $526.44 | $11.55 |
Enterprise Value | $47.12B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDEXX Laboratories (IDXX) trades at $595.76, up 1.55% on the day, with a bullish technical signal and strong fundamental performance. Recent Q2 2026 earnings beat expectations with EPS of $4.27 versus $3.94 expected, driven by 9% organic revenue growth. The company raised full-year EPS guidance to $14.69–14.94, reflecting robust demand in companion animal diagnostics. Valuation ratios remain elevated with a P/E of 41.23, supported by high profitability margins including a net income margin of 25.03% and ROE of 74.21%.
Outlook is positive given consistent earnings beats, international expansion, and product innovation, but risks include premium valuation sensitivity and competitive pressures. The consensus price target of $683.33 implies 14.7% upside, with 57% of analysts rating it Buy. Investors should weigh growth durability against high multiples.
MSTY trades at $12.45, down 0.8% on the day, with a bearish technical outlook showing 16 sell signals versus 1 buy signal. The ETF has experienced significant price erosion, with recent articles indicating a 67.45% decline in fund value while continuing weekly distributions. Support and resistance levels cluster tightly around $12-$13, indicating limited near-term price movement potential.
The outlook remains challenging as MSTY faces structural issues with its covered-call strategy capping upside while exposing investors to full downside risk. High distribution yields mask underlying NAV erosion, creating tax complications for investors. Continued pressure on the underlying Strategy (MSTR) position and Bitcoin volatility present ongoing headwinds for recovery.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →About YieldMax MSTR Option Income Strategy ETF
MSTY is an actively managed ETF that pursues a synthetic covered call strategy on MicroStrategy Incorporated (MSTR) stock. The fund primarily sells call options on MSTR and invests in U.S. Treasury securities and other high-quality collateral. Its goal is to generate monthly income from the option premiums. This strategy provides exposure to the volatile, Bitcoin-correlated growth potential of MSTR while seeking to deliver a high yield, though it caps the potential capital appreciation of the stock.
Read more on MSTY →
